Meloxicam Cyclodextrin Inclusion Complexes for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief due to its poor solubility, which can be addressed by forming an inclusion complex with cyclodextrins.
Innovation Solution
The formation of an inclusion complex of meloxicam with cyclodextrins, such as β-cyclodextrin, or in combination with bicarbonate, to enhance solubility and bioavailability, allowing for various administration routes including oral, intravenous, and parenteral methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is administered in conventional form, then the drug structure is simple and easy to manufacture, but the aqueous solubility is poor leading to reduced bioavailability
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers to complex with meloxicam, forming inclusion complexes that enhance aqueous solubility and bioavailability. The cyclodextrin cavity encapsulates the hydrophobic meloxicam molecule, allowing it to be transported in aqueous environments more effectively.
Solution Approach 2:
The patent creates composite formulations combining meloxicam with cyclodextrins and bicarbonate buffers. This composite approach integrates multiple components (meloxicam, cyclodextrin, bicarbonate) to achieve synergistic effects that improve solubility, stability, and bioavailability beyond what single components can provide.
2Speed
If meloxicam is administered in conventional form, then the formulation is simple, but the onset of pain relief is slow due to poor solubility
Solution Approach 1:
The patent changes the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This alters the dissolution rate and absorption kinetics, leading to faster onset of action. The complexation modifies how the drug interacts with aqueous environments and biological membranes.
Solution Approach 2:
Cyclodextrins act as mediators that facilitate faster dissolution and absorption of meloxicam. By pre-complexing the drug with cyclodextrins in the formulation, the system accelerates the rate at which meloxicam becomes available in solution for absorption, thereby speeding up pain relief onset.
3Reliability
If higher doses of meloxicam are administered to overcome poor solubility, then adequate therapeutic effect may be achieved, but gastrointestinal side effects increase
Solution Approach 1:
Cyclodextrins serve as protective intermediaries that shield meloxicam from direct contact with gastrointestinal tissues. The inclusion complex reduces the drug's irritant effects on the gastric mucosa while maintaining therapeutic efficacy, allowing lower doses to achieve the same effect with fewer side effects.
Solution Approach 2:
The patent changes the dissolution profile and absorption kinetics of meloxicam through cyclodextrin complexation. This results in more controlled and sustained release, preventing peak concentration spikes that could cause gastrointestinal irritation, while maintaining adequate therapeutic levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of cyclodextrin and bicarbonate complexes significantly increases the bioavailability of meloxicam, leading to faster and more effective pain relief, with improved plasma concentration profiles and reduced Tmax, allowing for lower doses and reduced gastrointestinal side effects.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.